Luan C, Li Y, Liu Z, Zhao C. Onco Targets Ther. 2020;13:3653–3665.
We, the Editors and Publisher of OncoTargets and Therapy, have retracted the published article.
Since publication, concerns have been raised about the integrity of the data in the article. This includes the duplication of images from Figures 3 and 5. Specifically,
The image for Figure 3A, HCT116, 0h, Blank has partial duplication with the images for Figure 3A, HT29, 0h, si-NC and HT29, 48 h, Blank and has been duplicated with the image for Figure 5D, 0h, Blank.
The image for Figure 3A, HCT116, 0h, LV-NC has partial duplication with the image for Figure 3A, HT29, 0h, Blank and has been duplicated with the image for Figure 5D, 0h, si-NC+inhibitor NC.
The image for Figure 3A, HCT116, 0h, LV-MALAT1, has been duplicated with the image for Figure 3A, HT116, 48 h, LV-NC and Figure 5D, 0h, si-MALAT1+inhibitor NC.
The image for Figure 3A, HCT116, 48 h, Blank has been duplicated with the image for Figure 3A, HT29, 0h, si-MALAT1 and Figure 5D, si-NC+miR-101-3p inhibitor.
The image for Figure 3A, HT29, 0h, Blank, has been duplicated with the image for Figure 3A, HT29, 48 h, si-NC and has partial duplication with the image for Figure 5D, 48h, si-NC+inhibitor NC.
When approached for an explanation, the authors did not respond to our queries, nor did they provide original data for their study. As verifying the validity of the published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.